Eledon Pharmaceuticals Company Leadership
| ELDN Stock | USD 4.25 0.04 0.95% |
Eledon Pharmaceuticals employs about 20 people. The company is managed by 8 executives with a total tenure of roughly 47 years, averaging almost 5.0 years of service per executive, having 2.5 employees per reported executive. Analysis of Eledon Pharmaceuticals' management performance can provide insight into the firm performance.
Eledon |
Eledon Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Eledon Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Eledon will maintain a workforce of about 20 employees by February 2025.Eledon Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3336) % which means that it has lost $0.3336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2536) %, meaning that it created substantial loss on money invested by shareholders. Eledon Pharmaceuticals' management efficiency ratios could be used to measure how well Eledon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of January 2025, Return On Tangible Assets is likely to drop to -0.86. In addition to that, Return On Capital Employed is likely to drop to -0.48. At this time, Eledon Pharmaceuticals' Non Currrent Assets Other are very stable compared to the past year. As of the 24th of January 2025, Other Current Assets is likely to grow to about 6.1 M, while Total Assets are likely to drop about 82.4 M.As of the 24th of January 2025, Common Stock Shares Outstanding is likely to grow to about 29.7 M, though Net Loss is likely to grow to (29.5 M).
Eledon Pharmaceuticals Workforce Comparison
Eledon Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,065. Eledon Pharmaceuticals claims roughly 20.0 in number of employees contributing just under 2% to equities under Health Care industry.
Eledon Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eledon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eledon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Eledon Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2022-03-01 | 1.25 | 10 | 8 | 658,000 | 683,654 |
| 2021-09-01 | 1.0 | 1 | 1 | 4,000 | 40,000 |
| 2020-12-01 | 0.8667 | 13 | 15 | 1,381,668 | 668,706 |
| 2020-09-01 | 0.4545 | 5 | 11 | 28,665 | 377,512 |
| 2019-06-01 | 0.5714 | 4 | 7 | 2,584,816 | 29,651 |
| 2017-06-01 | 1.3333 | 12 | 9 | 3,080,190 | 12,510 |
| 2016-03-01 | 1.5 | 3 | 2 | 36,015 | 28,015 |
| 2015-09-01 | 0.5 | 7 | 14 | 46,064 | 118,992 |
| 2015-06-01 | 0.6875 | 11 | 16 | 316,605 | 91,739 |
| 2015-03-01 | 0.3333 | 1 | 3 | 25,000 | 49,141 |
| 2014-09-01 | 0.1605 | 13 | 81 | 22,674,505 | 235,525,430 |
Eledon Pharmaceuticals Notable Stakeholders
An Eledon Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eledon Pharmaceuticals often face trade-offs trying to please all of them. Eledon Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eledon Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steven Perrin | Chief President | Profile | |
| Gregory Flesher | Consultant | Profile | |
| Bryan JD | Corporate Counsel | Profile | |
| John Herberger | Vice Operations | Profile | |
| Paul Little | Chief Officer | Profile | |
| David Hovland | Chief Officer | Profile | |
| FACS FACS | Chief Officer | Profile | |
| Jeffrey Bornstein | Chief Officer | Profile |
About Eledon Pharmaceuticals Management Performance
The success or failure of an entity such as Eledon Pharmaceuticals often depends on how effective the management is. Eledon Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eledon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eledon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (6.43) | (6.11) |
Eledon Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Eledon Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eledon Pharmaceuticals within its industry.Eledon Pharmaceuticals Manpower Efficiency
Return on Eledon Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5.8M | |
| Net Loss Per Executive | 14.6M | |
| Working Capital Per Employee | 2.6M | |
| Working Capital Per Executive | 6.5M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.